Podcasts about accommodations

Dr. Zamir Punja is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases and the applications of plant biotechnology for disease management. Since 2018, his work has focused on cannabis, identifying and describing a range of previously unreported pathogens affecting the crop and evaluating various methods for disease management.  Zamir is CannMed regular, having presented at 5 previous events. His presentations are always a highlight of the event because they often feature stunning electron microscope images showing plant structures and pathogens up close. In fact, his CannMed 22 presentation about glandular trichomes has gotten more than 300,000 views on our YouTube page, making it the most viewed CannMed presentation.  Zamir will again present at CannMed 26, this time about non-glandular trichomes in a presentation titled “Non-glandular trichomes in cannabis plants can secrete salts”.  During our conversation, we discuss: Non-glandular trichomes: What they are and what they do. How leaf spots, initially mistaken for disease, led to the finding that cannabis secretes excess fertilizer salts through these trichomes. Theories on why the plant would develop the ability to actively excrete excess salts. Practical guidance for cultivators on how to distinguish overfertilization from disease. Future research directions — comparing salt-tolerant vs. non-tolerant strains under varying salinity levels and exploring whether this mechanism explains cannabis’s resilience in drought-prone, high-salt environments. Thanks to This Episode’s Sponsor: Advanced Nutrients Advanced Nutrients will once again be a partner-level sponsor for the CannMed 26 Summit, and this year they have put together an amazing package for cultivators that includes: Full Access to all the presentations, networking events, and meals at the CannMed 26 summit  Accommodations at the Hyatt Regency Lake Tahoe  An elite package of Advanced Nutrients 8th Gen Fertilizers – enough for a complete crop valued at $11,126* 1x StrainSEEK® Whole Genome Sequence, valued at $547 – Provided by Medicinal Genomics That’s a $14,000 value for just $3,499!   Learn more at cannmedevents.com/package-options Additional Resources [Article] Non-glandular trichomes (epidermal hairs) in cannabis plants are capable of excreting nutrient salts under excessive fertilizer regimes [Video] Exploring the fascinating development of cannabinoid-producing trichomes Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

What if the key to innovation in your workplace isn't finding people who fit your culture, but transforming your culture to unlock brilliance that's been overlooked? Tara May, CEO of Aspiritech, has spent her career proving that when organizations create truly neuro-inclusive workplaces, everybody wins. In this conversation, Tara opens up about her personal journey, including raising an autistic son and her own OCD diagnosis in her 40s, and shares the practical frameworks any organization can use to go beyond diversity buzzwords and create real, measurable change. In this episode, you'll discover: Why 80% of autistic adults face unemployment, and what employers are missing The 'spiky cognitive profile' advantage and why neurodivergent talent can be 150% more productive What the 'ROI of Kindness' really means for your bottom line Three concrete steps to become a neuro-inclusive organization starting this week The canary in the coal mine: how accommodations for neurodivergent employees benefit everyone Why psychological safety isn't a soft skill — it's the engine of innovation About Tara May: Tara May is the CEO of Aspiritech, a tech services organization built on the belief that neurodivergent talent is a competitive advantage. With 25 years leading digital transformation at major media companies, Tara brings both executive credibility and lived experience to the movement for neuro-inclusive workplaces. Timestamps: [00:00] Intro — What if inclusion is the real innovation strategy? [01:24] Tara's origin story: An autistic son, a C-suite career, and a new mission [05:05] Neurodiversity belongs to all of us — the 86 billion neuron truth [06:56] Tara's own OCD diagnosis: 'It's okay to have needs' [10:03] Accommodations demystified: the water bottle story [13:20] The spiky cognitive profile and the strengths employers overlook [17:03] The index card meeting: introverted leadership in action [20:44] Universal design and the canary in the coal mine [25:27] 3 steps to becoming a neuro-inclusive organization [30:00] Psychological safety as the engine of digital transformation [35:11] How Aspiritech measures success — employees ARE the mission [38:54] One action you can take this week: ask 'what do I need?' [41:08] Where to find Tara and connect with Aspiritech Find Tara May at: www.aspiritech.org | LinkedIn: linkedin.com/in/tara-may Subscribe, leave a review at https://www.aworldofdifferencepodcast.com/reviews/new/, and share this episode. Visit our website for more resources. Mentioned in this episode: The Human Score — https://thehumanscore.org Find out how human-centric your organization really is with our 40-question survey and live dashboard. Get clear insights and practical steps to strengthen culture, trust, and performance. Host Lori Adams-Brown is one of the consultants in the Human Score Consultant Collective. Learn more about your ad choices. Visit megaphone.fm/adchoices

What if the key to innovation in your workplace isn't finding people who fit your culture, but transforming your culture to unlock brilliance that's been overlooked? Tara May, CEO of Aspiritech, has spent her career proving that when organizations create truly neuro-inclusive workplaces, everybody wins. In this conversation, Tara opens up about her personal journey, including raising an autistic son and her own OCD diagnosis in her 40s, and shares the practical frameworks any organization can use to go beyond diversity buzzwords and create real, measurable change. In this episode, you'll discover: Why 80% of autistic adults face unemployment, and what employers are missing The 'spiky cognitive profile' advantage and why neurodivergent talent can be 150% more productive What the 'ROI of Kindness' really means for your bottom line Three concrete steps to become a neuro-inclusive organization starting this week The canary in the coal mine: how accommodations for neurodivergent employees benefit everyone Why psychological safety isn't a soft skill — it's the engine of innovation About Tara May: Tara May is the CEO of Aspiritech, a tech services organization built on the belief that neurodivergent talent is a competitive advantage. With 25 years leading digital transformation at major media companies, Tara brings both executive credibility and lived experience to the movement for neuro-inclusive workplaces. Timestamps: [00:00] Intro — What if inclusion is the real innovation strategy? [01:24] Tara's origin story: An autistic son, a C-suite career, and a new mission [05:05] Neurodiversity belongs to all of us — the 86 billion neuron truth [06:56] Tara's own OCD diagnosis: 'It's okay to have needs' [10:03] Accommodations demystified: the water bottle story [13:20] The spiky cognitive profile and the strengths employers overlook [17:03] The index card meeting: introverted leadership in action [20:44] Universal design and the canary in the coal mine [25:27] 3 steps to becoming a neuro-inclusive organization [30:00] Psychological safety as the engine of digital transformation [35:11] How Aspiritech measures success — employees ARE the mission [38:54] One action you can take this week: ask 'what do I need?' [41:08] Where to find Tara and connect with Aspiritech Find Tara May at: www.aspiritech.org | LinkedIn: linkedin.com/in/tara-may Subscribe, leave a review at https://www.aworldofdifferencepodcast.com/reviews/new/, and share this episode. Visit our website for more resources. Mentioned in this episode: The Human Score — https://thehumanscore.org Find out how human-centric your organization really is with our 40-question survey and live dashboard. Get clear insights and practical steps to strengthen culture, trust, and performance. Host Lori Adams-Brown is one of the consultants in the Human Score Consultant Collective. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today I'm joined by Dr. Will Dobud, a social worker, researcher, and educator who has worked with adolescents and families across the United States, Australia, and Norway. Will is the co-author of Kids These Days: Understanding and Supporting Youth Mental Health, and he brings a refreshingly optimistic yet realistic perspective to the challenges facing today's young people.We dig into some truly provocative territory in this conversation. Will challenges the prevailing narrative that phones and social media are the root of the youth mental health crisis, drawing on historical moral panics — from kaleidoscopes to pinball machines — to argue that blanket bans rarely work. Instead, he advocates for digital integration through boundaries and parental involvement.We explore why more diagnoses, more medication, and more therapy haven't improved outcomes, and how the explosion of mental health labeling — especially around neurodivergence — may actually be doing more harm than good. Will shares his concerns about "label mania," the misuse of accommodations, and how identity politics have hijacked what was originally a movement toward inclusion. We also talk about the shortage of real-world experience for kids, the importance of rough-and-tumble play, and what parents can do to build connection instead of defaulting to control. This episode asks the hard questions: Are we crushing the spirit of youth with our own adult anxiety? And what would happen if we just gave kids something worth participating in?Dr. Will Dobud is a social worker, researcher, and educator who has worked with adolescents and families in the United States, Australia, and Norway. Will is from Washington, D.C., and divides his time between the United States and Australia each year. He is the author and editor of three books, including Kids These Days: Understanding and Supporting Youth Mental Health. Will is an award-winning researcher and educator who has received recognition for excellence in research, teaching, and crime prevention. Dr. Dobud is a Senior Lecturer in Social Work at Charles Sturt University, Australia's largest social work school. Will is an invited international speaker who conducts workshops for therapists and families worldwide. Will's research focuses on improving therapy outcomes for teenagers and promoting safe, ethical practices. He has investigated and written about America's Troubled Teen Industry, especially wilderness therapy. He has worked alongside advocates, survivors, researchers, and clinicians to protect youth from institutionalization and harm.WillDobud.comwww.kidsthesedaysbook.comFacebook: @WillDobudPhDX: @WillDobudInstagram: @WillDobud @Kids_These_Days_BookLinkedIn: https://www.linkedin.com/in/will-dobud-5209ab74/Substack: https://substack.com/@willdobudBooks mentioned in this episode:Kids These Days: Understanding and Supporting Youth Mental Health by Will Dobud and Nevin HarperThe Anxious Generation by Jonathan Haidti-Minds by Mari SwingleThe Spirit of Youth and the City Streets (1909) by Jane Addams[00:00:00] Start[00:02:46] Why Adults Get Trapped Trying to Fix Kids[00:06:06] What's Actually Going Right With Youth Today[00:10:17] Environmental Toxins and the Hard Questions[00:11:48] Digital Interference vs. Digital Integration[00:17:54] Can Kids Self-Regulate With Screens?[00:25:57] Phone-Free Schools: Solution or Distraction?[00:34:43] The Anxious Generation's Four Norms Problem[00:37:10] Putting Yourself in a Kid's Shoes[00:40:11] Experiential Learning and the Crowded Curriculum[00:48:07] Autism, Neurodivergence, and Label Mania[00:56:35] Identity Politics and Secondary Gain[01:04:04] Living Well With ADHD Without Hiding Behind It[01:12:11] Accommodations as Institutional Traps[01:16:22] Breaking Free From Therapeutic Dogma[01:18:46] Normies, Psychos, and Schizos[01:21:25] Institutional Exploitation in Mental Health[01:28:12] The Shortage of Experience and Risky Play[01:32:33] DC Punk Rock as Youth Participation Model[01:37:45] What Don't You Want to Change About Your Child?ROGD REPAIR Course + Community gives concerned parents instant access to over 120 lessons providing the psychological insights and communication tools you need to get through to your kid. Now featuring 24/7 personalized AI support implementing the tools with RepairBot! Use code SOMETHERAPIST2026 to take 50% off your first month.PODCOURSES: use code SOMETHERAPIST at LisaMustard.com/PodCoursesTALK TO ME: book a meeting.PRODUCTION: Looking for your own podcast producer? Visit PodsByNick.com and mention my podcast for 20% off your initial services.SUPPORT THE SHOW: subscribe, like, comment, & share or donate.Watch NO WAY BACK: The Reality of Gender-Affirming Care. Use code SOMETHERAPIST to take 20% off your order.MUSIC: Thanks to Joey Pecoraro for our song, “Half Awake,” used with gratitude & permission. ALL OTHER LINKS HERE. To support this show, please leave a rating & review on Apple, Spotify, or wherever you get your podcasts. Subscribe, like, comment & share via my YouTube channel. Or recommend this to a friend!Learn more about Do No Harm.Take $200 off your EightSleep Pod Pro Cover with code SOMETHERAPIST at EightSleep.com.Take 20% off all superfood beverages with code SOMETHERAPIST at Organifi.Check out my shop for book recommendations + wellness products.Show notes & transcript provided with the help of SwellAI.Special thanks to Joey Pecoraro for our theme song, “Half Awake,” used with gratitude and permission.Watch NO WAY BACK: The Reality of Gender-Affirming Care (our medical ethics documentary, formerly known as Affirmation Generation). Stream the film or purchase a DVD. Use code SOMETHERAPIST to take 20% off your order.

Ben and Nate tell a listener who recently obtained accommodations that her extra time shouldn't change how she approaches the test.Read more on our website. Email daily@lsatdemon.com with questions or comments. Watch this episode on YouTube!

Planning to cruise from Fort Lauderdale Florida on Disney Cruise line? Then this is the episode for you. I'll share my experience with the Brightline train from Orlando, how you can use Disney Cruise line transportation to get from local hotels to the port, and my top 3 picks for hotel accommodations nearby. Save this episode for your future Disney Cruise line vacation!I hope you enjoyed today's show. I'd love to connect with you over on Instagram @mountains_of_magic or Facebook at Fantastical Vacations by Daniele. If you would like help in planning an upcoming Disney or Universal vacation, email me at danielerobbins@fantasticalvacations.com or fill out a quote form to get started planning the magic Get A Quote Want the latest travel deals and all my tips for Disney, Universal and Cruising?Join my email newsletter  Want to try fetch rewards and get free gift cards by scanning receipts? Use my code 8G48W to get 2000 points at sign up. FETCH REWARDSMy Website mountainsofmagic.square.siteMusic from Uppbeat (free for Creators!):https://uppbeat.io/t/andrey-rossi/bring-the-funLicense code: E9BZCTS1O3JRPERX This podcast is not sponsored or supported by Fetch Rewards. Views of the host are her own. 

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different subtypes. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we're going to explore the evolving landscape of treatment strategies in head and neck cancer management, including locoregionally advanced head and neck squamous cell carcinoma, which happens to be on the rise in United States, in part due to spike in HPV-mediated oropharyngeal cancers. We're also going to discuss the emerging strategies of using blood-based biomarkers to really advance personalized therapy. Joining me for this discussion is Dr. Ari Rosenberg. He's a medical oncologist focused on head and neck cancer, and he's an associate professor – congratulations on the recent promotion – at the University of Chicago. The University of Chicago has really produced luminaries in this field, Dr. Rosenberg included. I've had the pleasure of getting to know Dr. Ezra Cohen over the years, who really had his grounding there, and of course Everett Vokes, former ASCO President. I'm really looking forward to this conversation, Ari. Thanks so much for joining us. Dr. Ari Rosenberg: Thanks, Monty. Thanks for the invitation. Dr. Monty Pal: You got it. And just a quick note for our listeners, our full disclosures are going to be in the transcript at the end of this episode. So let's start with the basics, if you don't mind. So, head and neck cancers are very diverse and they're challenging, right? In the sense that they're near vital organs, the treatments, you know, as we all saw during fellowship, if not now in clinical practice. They can really have such a major impact on vital organ function, speech, swallowing, et cetera. Can you just comment on head and neck cancers that are on the rise in the U.S.? I alluded to this briefly. Particularly, we've heard this in the context of colorectal cancer and so forth. Are you actually seeing younger adults being affected by this? Dr. Ari Rosenberg: Yeah, thanks for that. The vast majority of head and neck cancers are head and neck squamous cell carcinomas, as I'm sure many of the listeners recall as well from fellowship or their current training. And as you alluded to, the organ function, long-term and functional quality of life outcomes are quite important, particularly in the context that these develop in high value real estate, parts of our head and neck area that we use for speaking, swallowing, all sorts of other essential functions as well. As you also alluded to, we think of this in two different particular subtypes of head and neck cancer. The historical head and neck cancer from 50, 60 years ago was almost exclusively related to carcinogen exposure, tobacco, alcohol use, and that subtype of carcinogen-induced head and neck cancer has been slowly declining. However, over the last now several decades, we've been seeing an increase in primary oropharyngeal squamous cell carcinoma, mostly tonsil, base of tongue. These are attributable to HPV, human papillomavirus exposure. And that's now the majority of the head and neck cancers that we tend to see in our clinic. As you also alluded to, these have very different prognoses as well. HPV-related head and neck cancer has a much more favorable prognosis where much of the interest has been in can we de-intensify to optimize long-term function? But then the non-HPV-related head and neck cancer, or what we call HPV-negative head and neck cancer, continue to be very, very challenging. We only managed to cure about half of these folks, with many of these patients developing the current disease. These patients, in addition to being difficult to treat, also have major impacts both in terms of the treatments they undergo as well as their disease that can impact their function and quality of life. And you hinted at this a little bit, but we have been seeing an increase in younger patients with HPV-negative head and neck cancer as well, which is quite concerning. Younger patients, oftentimes never smokers, never drinkers, who are developing non-HPV-negative head and neck cancer. And that's been a little bit of a more recent trend that we've been seeing as well. So, definitely a lot of work to be done to optimize and improve outcomes across all of these different head and neck cancer subtypes. Dr. Monty Pal: I mean, I'm just curious, you know, in the context of colorectal cancer, one of the things that we talk about is the potential role of the microbiome driving some of these young-onset cancers with, you know, perhaps there being an impact on, for instance, inflammation and the gut and what have you. Tell me about head and neck cancer. Is this anything known as to why younger patients might be getting diagnosed with non-HPV type cancers? It's odd to me. Dr. Ari Rosenberg: Yeah, it's a great question. A lot of people are working on it. I think we folks have hypotheses, but it hasn't totally panned out exactly what's going on there. It does have a little bit more of a tendency towards women, whereas historically head and neck cancer is much more common in men than it is in women. But lots of people working on that, whether it's related to chronic inflammation, whether it's related to the microbiome. Whether it's related to dental exposure, dental work. So, a lot of folks trying to parse that out because I agree with you, it needs to be identified alongside improving treatment paradigms for these patients, the young ones and the older patients as well. Dr. Monty Pal: Interesting, interesting. You know, one of the phenomena that was sort of coming around when I was in training 25 years ago was this role of sort of induction therapy for head and neck cancers. And of course, it's really come full circle now to include checkpoint inhibitors and so forth. Tell me a little bit about this and how you apply it, maybe in an HPV-mediated context, maybe in a non-HPV context. Dr. Ari Rosenberg: Yeah, absolutely. Induction chemotherapy, as you alluded to, or neoadjuvant chemotherapy, depending on what the locoregional treatment approach is. Similar to other cancer types where systemic control early on has many potential advantages in this setting. Now, in head and neck cancer, even though induction chemotherapy is quite active in head and neck cancer, both HPV-positive and HPV-negative with pretty good response rates. A survival advantage for all comers with local regionally advanced disease remains unproven. There's been two randomized trials, both underpowered, but essentially did not show a survival advantage, showing that induction chemotherapy for all patients with locoregionally advanced and neck cancer can't be justified for a survival advantage. That being said though, there remains a number of potential advantages of giving induction or neoadjuvant chemotherapy, of course, improving systemic control and debulking the disease early on has potential advantages, and predicting the responsiveness to subsequent radiation treatment. We know for some time in head and neck cancer that the percentage of shrinkage or the response to induction chemotherapy actually predicts outcome related to radiation as a dynamic biomarker where response can be used to select patients, for example, for de-escalated radiation has been an area of active investigation, active research. And it also remains a key opportunity to evaluate predictive biomarkers and understanding pre and post treatment to better understand the biology. I'll just add to your question that recently over this past year, we also saw phase 3 data for neoadjuvant immunotherapy for a subset of head and neck cancer that is surgically resectable. And so that's reintroducing the potential benefit in the immunotherapy era of incorporating immunotherapy in the neoadjuvant or the induction setting as part of the evolving treatment paradigm for these diseases. Dr. Monty Pal: That's really interesting. And you kind of alluded to already several topics that I plan to hit on, you know, for instance, the role of immune checkpoint inhibitors, induction, chemotherapy, and so forth. And you started to touch on biomarkers. And of course, I think that's something near and dear to many of us in academic oncology. One thing that we've started talking a lot about in the context of colorectal cancer is circulating tumor DNA. How do you think this might fit in the context of head and neck cancer? Can you give us a flavor for that? Dr. Ari Rosenberg: Yeah, absolutely. In head and neck cancer, the current landscape is most developed for circulating tumor DNA for HPV-related head and neck cancer. The advantage of HPV-related head neck cancer is that you have a distinctive HPV DNA that does tend to spill out into the peripheral blood and can be detected using various different blood-based assays. And because of that advantage as a tissue agnostic approach, it turns out that a number of HPV DNA plasma assays are actually quite sensitive and quite specific. And a number of them have indeed been commercialized. Of course, not only for detecting a baseline, but also grading responsiveness during treatment and probably most importantly in the post-treatment surveillance setting, the detection of HPV DNA in the plasma remains a very important and substantial predictor of developing recurrent disease. There's been a number of trials that have been emerging looking at ctDNA and HPV-related head and neck cancer, using it, for example, as a strategy to deescalate patients. That was something we saw this past ASCO from the Dana-Farber group, and also using it to early detect recurrence and potentially intervene earlier for patients with minimal residual disease positivity. So, that remains evolving and as many folks are, I think, already using it in the clinic. But ctDNA also has a lot of potential for HPV-negative head and neck cancer. This is actually a bit more challenging to develop because you don't have that HPV DNA that you can track predictably because the tumor is an HPV- negative disease are much more heterogeneous, but there are a number of data that are coming out both for personalized assays such as Signatera or some of the other assays that require tumor. Unlike colon cancer, which you referenced, where most patients get surgery upfront, in head and neck cancer, many of the patients receive non-surgical pre-chemoradiation. So sometimes the amount of tumor available to generate a personalized assay is more limited and can be one of the challenges that we see in head neck cancer. But certainly that also seems to be emerging. And there's also further assays that are being developed for HPV-negative head neck cancers, such as methylomic signatures and others that may be tissue informed or tissue agnostic. And these are also emerging, particularly in the post-treatment surveillance setting as strong predictors of recurrent disease. So while we're certainly behind some of these other more common tumor types, colon cancer, lung cancer, we're right there with them and more and more trials are going report out, including a number of trials in our upcoming [University of Chicago] Head and Neck Cancer Symposium where I'll be presenting some data and others in the field will be presenting some data looking at ctDNA both for HPV-positive and for HPV- negative to try to improve outcomes for these patients. Dr. Monty Pal: That's so interesting. I've got to tell you that in kidney cancer, what I deal with day to day is a very low shedding disease, right? So techniques as opposed to ctDNA looking for tumor-informed information, that might be less preferred to something like methylomics where you might not necessarily be so contingent on what's happening in the primary tumor. I'm really interested in you mentioning that. Just a point of clarification, this is something I'm trying to wrap my head around. You'd mentioned circulating tumor HPV DNA, right? I assume this is markedly different from just looking for HPV titers in the patient, right? So is this actually incorporated elements of HPV within, you know, essentially host genome, if you will? Dr. Ari Rosenberg: Yeah, correct. This is circulating tumor HPV DNA. And we think of it biologically as a plasma-based tumor DNA biomarker that's specific for HPV-related head and neck cancers. Dr. Monty Pal: Got it, got it. It makes me wonder whether or not this might be applicable to diseases like cervical cancer and so forth where there's also extensively, you know, biology driven by HPV. Is that fair? Dr. Ari Rosenberg: Yes, definitely. And in the head and neck cancer field, much of this ctDNA actually was derived from a different viral mediated head neck cancer, is less common in the U.S., but nasopharyngeal cancer, which is oftentimes associated with EBV. That has been a biomarker for quite some time in nasopharyngeal cancer. Of course, in places where EBV-associated nasopharyngeal cancer, is endemic, such as East Asia, this has been around for quite some time, but we've been using that in the U.S., and there's been trials that have used EBV DNA plasma to predict recurrence and stratify for adjuvant treatment, for example. And so now with HPV, it's much more applicable to our US population because the vast majority of our head and neck cancer patients that we see in the US that are viral mediated in the US tend to be HPV-related. So having assays that we can use to improve outcomes for that biological subset remains of particular interest for us. Dr. Monty Pal: Yeah, that's fascinating. By the way, for the fellows listening, there's tons of boards pearls here that Dr. Rosenberg shared, EBV-associated cancers, the role of HPV and treatment association. So if you're recertifying anytime soon, I definitely think there's notes to take from this conversation indeed. I wanted to shift gears a little bit. And obviously, you're a prolific researcher. I don't think anyone goes through their fellowship in medical oncology without recounting these experiences of our head and neck patients really suffering from treatment-related toxicities. It's a real challenge. And I'm just wondering, I know a big body of work that you're focused on is really using multimodality treatment paradigms to perhaps reduce the cumulative treatment burden of patients with head and neck cancers. Can you talk about that a little bit? Dr. Ari Rosenberg: Yeah, definitely. Thanks for the question. And before I start going into some of the strategies, I'll just say that head and neck cancer, this is particularly for the fellows that are listening as well, just in reference to your prior comment, that this is really a multidisciplinary disease. At our center, all head and neck cancer patients are seen upfront at that first visit by all three specialties, med onc, rad onc, and surgery, because the choice and sequencing of modalities to optimize not only survival, but also functional quality of life outcome is so critical. And I think that's probably the biggest takeaway for anyone who treats a lot of head and neck cancer or will be treating a lot of head and neck cancer in the clinic. But in terms of more specific attempts at trying to optimize some of those parameters that you described, we really think about these separately in terms of HPV-positive and HPV-negative head and neck cancer. For HPV-positive head and neck cancer, the cure rates are quite high with chemo radiation, although not for everyone. There's still about 15, 10 to 15 % of folks that will develop a recurrence. But for the vast majority of patients, standard chemoradiation is quite a cure to therapy, but the toxicity associated with that can be quite substantial. And so there's been a number of attempts to try to deescalate treatment. It turns out that deescalating everyone with locoregionally advanced HPV-positive head and neck cancer is not a good strategy because it's not able to select out the patients that really do need full dose treatment. And we have seen some negative trials that show inferior outcomes when everyone is deescalated. But what does remain promising is again, trying to select out who the best candidates are for deescalated treatment. The folks at MSK have hypoxia imaging that they're using in trials that looks quite promising to select for the more favorable deescalatable biology. At our center, we've been interested in using induction chemotherapy to stratify response and select patients for deescalated treatment with excellent survival outcomes and reduce toxicity with deescalated treatment. And more recently, ctDNA that us and other groups, such as the Dana-Farber group, is using. And that also looks quite promising. Again, how do you select the patient who will do well with less radiation versus the ones that really need the full doses and volumes of radiation? And then for HPV-negative head and neck cancer, this is a much trickier disease because already the survival outcomes are not like we want it to be. Trying to figure out how to improve survival outcomes remains an important thing. Using immunotherapy seems to be one of the key cornerstones to that. But these are patients that also suffer from a lot of toxicity related to their treatment. We completed a trial not too long ago that we published this past year where we, in HPV-negative head and neck cancer patients, de-intensified the radiation for responders to neoadjuvant chemoimmunotherapy. And those patients did similar, if not even a little bit better, than the non-responders who got full dose treatment. So something that does warrant further investigation as well. How do we not only improve survival for those patients, but also reduce some of the long-term toxicities? Dr. Monty Pal: This is brilliant. I'm taking so many notes as you were mentioning these items. There are so many areas where I think the research crosses over. I already mentioned, know, ctDNA, for instance, and metabolomics and the places where that might apply to kidney cancer. The hypoxia imaging really caught my ear too. Obviously, kidney cancer is disease highly predicated on hypoxia. So thank you for all of this. We've got about a minute or so. So, I'm going to ask you for a really tall task here. Can you tell us what you foresee being some of the biggest challenges that sort of lie ahead and head and neck cancer. You've already kind of alluded to it with ongoing research, but if you had to pick maybe 2, 3 problems, the very most that we really need to get to and head and neck cancer, what would that be? Dr. Ari Rosenberg: Yeah, that's a great question. Obviously, lots of things to be done, but if I'm going to limit it to just a couple, I would say number one is really trying to improve the survival for HPV negative local regionally advanced head and neck cancer. We talked early on about how we are seeing, you know, of course we see many of these people that were smokers and drinkers, but also seeing these in younger patients, in patients without a history of tobacco use. Some of these are very biologically aggressive and we need better treatments beyond surgery, beyond chemo radiation, beyond immunotherapy to improve outcomes for these patients and cure more of them. So, I would say that's one big area. And the other is, which we didn't speak about so much in this talk, but remains one of the biggest challenges that we see in the clinic is the recurrent metastatic head and neck cancer patients. This is an incredibly challenging disease to treat, not only with poor survival, but also with substantial impacts on quality of life and function. mean, these are bad recurrences that cause a lot of pain, functional deficits, really impacts quality of life as well. So developing novel therapies, many of which are currently in clinical trials and many of which are currently continuing to be developed, remains so critical. How do we develop better systemic therapies, better targeted therapies, better biomarkers for recurrent metastatic head neck cancer to improve their survival and quality of life and functional outcomes. Those are the two big areas that require the most work at this time within the head and neck cancer field. Dr. Monty Pal: That's brilliant. I mean, I have to tell you I could probably talk to you all day about this, such a fascinating topic. It's a very exciting time in the field. Thank you, Dr. Rosenberg, for all your incredible contributions and thanks for sharing with us your insights on the ASCO Daily News Podcast. Dr. Ari Rosenberg: Yeah, and thanks for the introduction. Hope to do it again soon. Dr. Monty Pal: And many thanks to our listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. More on today's speakers:      Dr. Monty Pal   @montypal  Dr. Ari Rosenberg @AriRosenbergMD Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:       Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical      Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Ari Rosenberg:     Stock and Other Ownership Interests: Privo Technologies Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas Pharma, Regeneron, RAPT Therapeutics, Geovax Labs, Janssen, Summit Therapeutics Speakers' Bureau: Coherus Biosciences Research Funding (Inst.): Hookipa Biotech, EMD Serono, Purple Biotech, Bristol-Myers Squibb/Celgene, BeiGene, Abbvie, Astellas Pharma, Pfizer, Janux Therapeutics

In this episode Clinical Psychologist Dr. Alex Klein and I discuss ten common misconceptions about Pathological Demand Avoidance or Pervasive Drive for Autonomy.Here are five from Dr. Klein:The parent of a PDAer is doing something wrong, especially if they've lowered demands.If a PDA child did something yesterday, they can do it again today.Accommodations won't prepare PDA kids for the real world.Progress made by a PDA child is measured by what we see on the surface.Behaviorism (behavioral parenting) will be enough.And here are five from me, in strong collaboration with my PDA 11- and 7-year-olds:PDA kids are bad kids.How much freedom PDA kids need.It's not behavioral, it's stress.Why and when they can hide nervous system stress.Potatoes are green and they smell like poop :)I hope the episode is helpful to you!xo,CaseyPS - New to PDA? You can take our free 6-minute quiz to learn how well your child or teen fits the profile.

When you need expert individual support with skill, strategy, behavior, or body of knowledge, you'll probably reach out to a tutor or coach. How do those roles differ, and how can you get the most out of them? Amy and Mike invited test prep professional Scott Clyburn to define coaching for academic success. What are five things you will learn in this episode? Is there a difference between teaching and coaching? What are simple conversation habits that keep students in the driver's seat in learning? What is the best way to benchmark executive function skills?  Why is it valuable to look at habits you want to change as experiments? What are the most common pitfalls when tutors try to shift to a coaching approach? MEET OUR GUEST Scott Clyburn holds degrees from the University of Virginia and Yale University and is the founder and director of North Avenue Education, a premier test-preparation and study-skills firm based in Portland, Oregon. Originally from Houston, Texas, Scott has taught in both secondary and higher education and has been a professional tutor since 2005. He sees tutoring as an opportunity for any student to become a better learner. Scott specializes in coaching students with LD and is motivated by seeing his students transform their potential into action. Scott is the author of the North Avenue Guide to Study Skills, which will be published this winter and licensable by tutors and orgs in 2026.  Scott previously appeared on the podcast in episode 97 to discuss Test Prep for Students with Accommodations. Find Scott at scott.clyburn@northaveeducation.com or https://northaveeducation.com. LINKS The difference between tutoring and academic coaching RELATED EPISODES EFFECTIVE STUDY SKILLS FOR TEST PREPARATION HOW TO TEACH STUDENTS TO STUDY EFFECTIVELY THE THREE CORE EXECUTIVE FUNCTIONS AND TEST PREP WHY PROFESSIONALISM IN TUTORS MATTERS WHY YOU WANT TO WORK WITH A CAREER TUTOR ABOUT THIS PODCAST Tests and the Rest is THE college admissions industry podcast. Explore all of our episodes on the show page. ABOUT YOUR HOSTS Mike Bergin is the president of Chariot Learning and founder of TestBright, Roots2Words, and College Eagle. Amy Seeley is the president of Seeley Test Pros and LEAP. If you're interested in working with Mike and/or Amy for test preparation, training, or consulting, get in touch through our contact page.

Leaves of absence are complicated, highly regulated, and often misunderstood in dental practices. In this episode, Kirk Behrendt sits down with Alan Twigg, HR expert at Ben Erickson Administrative Services, to explain how leaves of absence actually work, why documentation matters, and how dentists can protect their practices while treating team members fairly. You'll learn how to identify protected leave, handle medical and mental health requests, manage return-to-work issues, and avoid common mistakes that lead to liability. Listen to Episode 1004 of The Best Practices Show!Main TakeawaysA leave of absence typically applies when an employee will be out for more than one week and may trigger state or federal protections.The reason for the leave determines which laws apply, so employers must clearly document whether the leave is due to pregnancy, medical conditions, mental health, or family care.Mental health conditions are medical conditions and may qualify for protected leave under disability laws.Every leave of absence should have a documented start date and an estimated return date to prevent confusion and legal risk.Medical certifications and job descriptions are essential tools for determining work restrictions and accommodations.Most leaves of absence are unpaid, but accrued PTO is usually used at the beginning of the leave as wage replacement.Employees on protected leave generally must be reinstated to the same role, pay, and hours unless the position is legitimately eliminated.Snippets00:39 What qualifies as a leave of absence versus regular sick time.02:06 Why state and federal leave laws vary by location and practice size.04:18 Mental health as a protected medical condition.07:38 Pregnancy and disability protections explained.10:40 Why every leave needs a defined return date.13:27 Risks of replacing an employee on protected leave.14:21 Medical certification and job descriptions.17:38 Accommodations and undue hardship.19:29 Health insurance and benefits during leave.20:55 Using accrued PTO during a leave of absence.24:27 Medical release and return-to-work requirements.27:33 When a leave of absence is not legally protected.30:40 Documentation tips to protect the practice.Guest Bio/Guest ResourcesAlan Twigg is an HR specialist with Ben Erickson Administrative...

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

In this deeply human and inspiring conversation, Bart sits down with Dr. Eric Fishon — author, educator, disability advocate, and nonprofit leader — to explore the lived reality of unseen disabilities and the power of advocacy, empathy, and inclusion. Dr. Eric shares his journey from a successful corporate career in customer experience and organizational culture to discovering his diagnoses of narcolepsy, chronic fatigue, ADHD, anxiety, and depression later in life. What followed was not an ending, but a reinvention. Through his Doctor Disruptor platform, Xtermigator Kids, and his work with the Invisible Disabilities Association, Dr. Eric is helping individuals and families understand that disability is not inabilityand that different is, in fact, beautiful.Major Takeaways / LearningsUnseen disabilities are real — even when others can't see them. Validation can be life‑changing.Diagnosis brings clarity, not limitation. Knowing what you're dealing with opens the door to tools, accommodations, and self‑compassion.It's okay to not be okay. Giving yourself grace is a critical step toward healing and growth.Advocacy often begins with personal struggle. Dr. Eric turned his own challenges into a mission to help others.Accommodations are not special treatment — they're access. Education and workplaces still have work to do.Helping others creates purpose and fulfillment. Service can be as powerful as medicine.Technology and AI can be equalizers. The right tools help people with limited energy amplify their impact.Disability does not define your ceiling. With support, inclusion, and understanding, potential expands.Memorable Quotes“It's okay to not be okay.”“Disability is not an inability — it can be your greatest superpower.”“Those letters after your name mean nothing if you're not helping someone behind you.”“Helping others gives a high no medicine can replace.”“Never forget where you've been — and turn around to help someone else get there.” Why It Matters / How to Use ItThis episode is a powerful reminder that many of the struggles people carry are invisible, and that empathy, awareness, and inclusion are leadership skills, not extras. Dr. Eric Fishon's story offers hope to anyone who has felt misunderstood, dismissed, or alone in their challenges. Whether you're living with an unseen disability, supporting someone who is, or leading a team, this conversation encourages you to ask for help, give grace, and use your experiences to lift others. It's a call to redefine success, not by what we overcome alone, but by how we help others rise with us.

In the latest episode of The Celiac Project Podcast, Mike checks in on Cam to see how his return to college life at the University of Illinois Chicago is going. Cam shares the realities of living in a dorm, navigating a required meal plan with celiac disease, and advocating for safe gluten-free food on campus. Cam shares what's working, where systems fall short, and the challenges of getting glutened and securing academic accommodations. A candid, informative conversation for anyone with celiac disease, or anyone helping a student prepare for college life gluten-free.Listen to the full episode here: https://celiacprojectpodcast.libsyn.com/I would love to hear from you! Leave your messages for Andrea at contact@baltimoreglutenfree.com and check out www.baltimoreglutenfree.comInstagramFacebookGluten Free College 101Website: www.glutenfreecollege.comFacebook: http://www.Facebook.com/Glutenfreecollege Hosted on Acast. See acast.com/privacy for more information.

Dan Schorr and Alyssa-Rae McGinn are joined by Brigid Harrington and Amy Fabiano, senior attorneys at Hunton Andrews Kurth, to discuss pregnancy accommodations and related issues (Episode 164) ---- Brigid Harrington: https://www.hunton.com/people/brigid-harrington Amy Fabiano: https://www.hunton.com/people/amy-fabiano Dan Schorr, LLC: https://danschorrllc.com/ Dan's fiction reading and writing Substack: https://danschorr.substack.com/ Dan Schorr Books: https://danschorrbooks.com/ 

We are joined in this episode by Stacey Shubitz, K-6 literacy consultant, a former elementary school teacher, and the co-founder of the Two Writing Teachers blog and podcast. Her forthcoming book, Make the School System Work for Your Child with Disabilities: Empowering Kids for the Future, empowers parents to navigate the special education system. In this episode, we talk openly about what it really takes to support a child with learning challenges in today's school system. Drawing from decades of experience on both sides of the table, Stacey shares why she wrote Make the School System Work for Your Child with Disabilities and what she wishes someone had told her when she was first trying to make sense of evaluations, IEP meetings, and endless paperwork. Our conversation centers on some of the practical mindset shifts that can help change everything for families, with Stacey explaining why leading with a child's strengths and not just their needs is so important for confidence and motivation. She also addresses disability language head-on, discussing why it is that naming disability isn't limiting but instead opens doors to services, legal protections, and access that families often don't realize they're entitled to. Throughout the episode, we highlight how knowledge of data, timelines, rights, and documentation can shift the power dynamic and help parents advocate more effectively. We offer some concrete guidance on when to push for evaluations, why waiting too long can do a lot of harm, and how to ask for progress data without feeling confrontational. Stacey also shares what makes IEP meetings feel collaborative instead of adversarial, from simple preparation strategies to small human touches that ease tension. Communication comes up again and again: how approaching teachers with curiosity, clarity, and respect can lead to better outcomes for kids! Stacey also speaks candidly about burnout, emotional exhaustion, and why joy isn't optional but protective. This conversation offers reassurance, realism, and a clear-eyed look at how parents can show up informed, empowered, and grounded while advocating for their children. Show Notes: [2:32] - Hear how Stacey's experiences with IEPs inspired her to help other parents. [4:04] - Stacey describes leading with strengths, not just challenges or disabilities. [6:03] - Highlighting positives alongside challenges helps children see themselves as capable. [9:42] - Stacey argues that children should know their rights and services so that they can advocate for themselves. [12:49] - It's so important for parents to monitor progress, request data, and push for evaluations when their child isn't advancing. [14:58] - Stacey adds that it's also essential to advocate firmly and request evaluations when interventions aren't producing results. [16:20] - Preparing for meetings with clarity, human touches, and understanding who's present can help make discussions more productive. [19:44] - Coming to meetings prepared with documents in advance helps balance power and supports advocacy. [23:04] - Stacey discusses how reviewing IEPs in advance can help ensure more effective teacher interactions. [25:00] - Approaching teachers with curiosity and gathering accurate information helps promote calm, productive conversations around school. [28:18] - Stacey gives an example of how being open about personal struggles allows teachers to provide better support for children. [30:33] - Stacey asserts that assuming positive intentions about teachers helps lead to collaboration and avoids unnecessary conflict. [32:07] - Stacey wishes that she had known sooner how important it is to read the procedural safeguards book to understand parental rights and timelines. [34:12] - Stacey expresses that she has learned that intentionally curating joy and connection can help prevent burnout. [37:05] - Joy is a legitimate form of intervention. Links and Related Resources: Stacey Shubitz - Make the School System Work for Your Child with Disabilities: Empowering Kids for the Future Episode 164: 5 Keys to Productive IEPs with April Rehrig Episode 238: Dismantling DEI and the Department of Education: How Changes Impact Your Child with Vickie Brett & Amanda Selogie Episode 246: Accommodations, Modifications, or Remediation? How to Know What Your Child Really Needs with Amy Cushner   Connect with Stacey Shubitz: Stacey's Website Email: stacey@staceyshubitz.com Stacey's Substack Two Writing Teachers Website  

In Episode 137 of Let's Talk Learning Disabilities, Laurie and Sydney discuss why many students and adults seek testing accommodations only when facing high-stakes exams such as the SAT, ACT, LSAT, MCAT, GRE, bar exam, or medical licensing tests. Requests often come from two groups: high-school students whose families are newly aware of the accommodations process, and older college or graduate students who are suddenly told--often by tutors or counselors--that extra time could help them. For many, this realization comes too late, triggering panic as they confront a complex and bureaucratic approval system they never knew existed.Resources:Contact info for the podcast: letstalklearningdisabilities@gmail.comE-Diagnostic Learning Website: https://ediagnosticlearning.comFacebook: https://www.facebook.com/eDiaglearning/Twitter: @diaglearningLinkedIn: https://www.linkedin.com/company/diagnostic-learning-services/Instagram: @diaglearning

Jan. 8, 2026- In December, state law was strengthened to protect New Yorkers who request reasonable accommodations in public places, like at work. We explore the significance of this anti-retaliation measure and consider the merits of updating New York's paid medical leave program with Jesse Workman, a senior staff attorney with A Better Balance.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

In this episode, Lisa and Annie discuss:Career planning when chronic health conditions or physical disabilities affect daily functioningSelf-advocacy and accommodations across education, training, and employmentAligning career choices with realistic capacity and long-term sustainabilityUsing real-world experiences and conversations to validate career fitKey Takeaways: College provides a structured environment where students can learn to articulate how their condition affects them, practice requesting accommodations, and build confidence navigating formal systems they will later encounter in the workplace.Accommodations support access but do not eliminate essential job functions, making it critical to assess whether the physical, cognitive, and stamina demands of a role can be met consistently over time.Hands-on validation through internships, clinicals, job shadows, and informational interviews reveals the lived reality of a job in ways that academic requirements alone cannot.Sustainable career planning requires honest conversations about energy limits, recovery time, and quality of life, rather than defaulting to paths that are technically possible but personally draining. “You have to be comfortable talking about your condition and your needs.” – Annie TulkinAbout Annie Tulkin: Annie Tulkin is the CEO and Founder of Accessible College, as well as an educator, author, and public speaker. She is an expert in college preparation and transition for students with physical disabilities and health conditions, and has worked in the disability field for her entire professional career. She holds degrees from DePaul University and the University of Wisconsin–Madison, was a Peace Corps Volunteer and Fulbright Fellow in Mongolia, and resides in Silver Spring, MD, with her husband and daughter.Episode References:Job Accommodation Network (JAN): https://askjan.org/Diabetes Link (formerly College Diabetes Network): https://thediabeteslink.org/Christopher & Dana Reeve Foundation: https://www.christopherreeve.org/#099 Navigating College with Physical Disabilities and Health Conditions with Annie Tulkin: https://www.flourishcoachingco.com/podcast/099-navigating-college-with-physical-disabilities-and-health-conditions-with-annie-tulkin/Get Lisa's Free on-demand video: How-to guide for your teen to choose the right major, college, & career...(without painting themselves into a corner, missing crucial deadlines, or risking choices you both regret). flourishcoachingco.com/video Connect with Annie:Instagram: https://www.instagram.com/accessiblecollege/Facebook: https://www.facebook.com/accessiblecollege/LinkedIn: https://www.linkedin.com/in/annie-tulkin-3b66b719/Website: https://accessiblecollege.com/Connect with Lisa:Website: https://www.flourishcoachingco.com/YouTube: https://www.youtube.com/@flourishcoachingcoFacebook: https://www.facebook.com/flourishcoachingco/ Instagram: https://www.instagram.com/flourishcoachingco/LinkedIn: https://www.linkedin.com/company/flourish-coaching-co

Episode: Jason Staples and Stephen Carlson try to ruin your Nativity! Jason discusses Stephen's essay "The Accommodations of Joseph and Mary in Bethlehem: Κατάλυμα in Luke 2:7." They also discuss when and how Mary and Joseph get married, the census in Luke 2:2, and ... (wait for it) ... the Spanish Inquisition.  Guest: Dr. Stephen Carlson is Associate Professor in the Biblical and Early Christian Studies program at the Australian Catholic University. He's the author of three books, The Gospel Hoax: Morton Smith's Invention of Secret Mark (Baylor, 2007), which debunked the "Secret Gospel of Mark"; The Text of Galatians and its History (Mohr Siebeck, 2014), which applied state-of-the-art computer phylogenetic software he wrote himself to produce a family tree of ninety-two manuscripts and witnesses of Galatians; and Papias of Hierapolis' Exposition of Dominical Oracles (Oxford, 2021), the most complete edition of the fragments of Papias of Hierapolis, a second-century Christian commentator. He is also the author of numerous peer-reviewed journal articles, including his article on the so-called "inn" in Luke's infancy account (under discussion in this episode) and essays on the donkeys in Matthew's triumphal entry: Stephen C. Carlson, “‘The Jenny and the Colt' in Matthew's Messianic Entry, Part 1: Matthew 21:5 as a Reading of Zechariah 9:9 in Light of Mark 11:1-10,” in the Catholic Biblical Quarterly, volume 81, number 1 (January 2019), pages 62-84 (link). Stephen C. Carlson, “‘The Jenny and the Colt' in Matthew's Messianic Entry, Part 2: Matthew 21:7 as a Reading of Mark 11:7 in Light of Zechariah 9:9,” in the Catholic Biblical Quarterly, volume 81, number 2 (April 2019), pages 235-251 (link). HERE is a link to the article "Luke 2:2 and the Census."  

After surveying over 1,000 HR leaders, AbsenceSoft's 2026 State of Leave and Accommodations report revealed that the nature of leave and accommodations requests has fundamentally shifted in ways most compliance professionals aren't prepared for. For the third year running, caseloads continue climbing, but it's not just the volume that's changed. The types of requests employees are making, the tools HR teams are using to manage them, and the compliance risks lurking in seemingly helpful shortcuts are creating a perfect storm. If you're still managing your programs the way you did three years ago, or if you think AI is just a future concern, this conversation will change how you think about risk, resources, and what it takes to stay compliant in 2026.

40 Trips to France: Plus a French Christmas Feast with Annie & Elyse opens with host Annie Sargent welcoming back longtime traveler Janice Chung, who has now visited France 40 times. This episode explores why France keeps calling people back and how repeat travel changes the way you experience the country. Listen to this episode ad-free Janice explains why France feels like home to her. She talks about slowing down, speaking French even when it's imperfect, and choosing experiences over checklists. She shares how she plans trips around things that excite her. Sometimes it's a race, like the Adidas 10K in Paris. Sometimes it's a scenic train ride in the Ardèche. Other times it's simply walking for hours and letting the day unfold. Annie and Janice discuss favorite regions, especially lesser-known places like the Aveyron. They talk about beautiful villages, local food like aligot, and why these areas remain less touristy. Janice also explains how she mixes trains, rental cars, biking, and walking depending on where she goes. This episode also looks at how France has changed over the decades. Janice remembers dirtier streets, heavier smoking, and more car traffic. Today, she notices cleaner cities, contactless payments everywhere, and easier trip planning thanks to technology. Prices have gone up, especially in Paris, but great value still exists outside major cities. The episode ends with a festive magazine segment. Annie Sargent and Elyse Rivin talk about French Christmas traditions. They cover chocolate, foie gras, oysters, cheese, bûche de Noël, and how bakeries prepare for the holidays. It's practical, warm, and very French. If you love real conversations about travel, food, and life in France, this episode is for you. Subscribe to the Join Us in France Travel Podcast on your favorite podcast app, on Spotify, or on YouTube so you never miss an episode. Table of Contents for this Episode [00:00:16] Introduction and Welcome [00:00:31] Today on the podcast [00:00:49] Podcast supporters [00:01:20] Magazine segment [00:02:31] 40 Visits to France with Janice Chung [00:02:57] Why France Feels Like Home [00:04:02] Exploring Lesser-Known Regions [00:04:49] Unique Experiences in Ardèche [00:07:38] Running and Racing in France [00:08:53] Travel Preferences and Challenges [00:09:58] Biking Adventures in France [00:17:12] Changes in France Over the Years [00:22:14] Travel Duration and Cat Care [00:23:05] Discovering a Love for France [00:23:54] Starting a Travel Blog [00:25:22] Unique Travel Experiences [00:26:16] Booking Trips and Accommodations [00:28:14] Navigating French Language and Culture [00:29:55] Favorite French Foods [00:30:46] Travel Tips for First-Time Visitors [00:33:02] Cash and Contactless Payments [00:35:03] Booking accommodation [00:39:26] Medical Encounters in France [00:42:51] Final Thoughts and Future Plans [00:43:32] Christmas Foods with Elyse and Annie More episodes about Christmas in France #JoinUsInFrance, #FrancePodcast, #TravelFrance, #FrenchCulture, #ExploreFrance, #DiscoverFrance, #FranceTravelTips, #RealFrance, #Francophile, #FranceAdventures, #SlowTravelFrance, #FranceBeyondParis, #FrenchChristmas, #ChristmasInFrance, #RepeatTravel, #FranceLovers, #TravelPodcast, #FranceByTrain, #FranceFood, #LifeInFrance

Students in Special Education deserve to be considered and planned for in school safety operations. In this conversation, THINK+change learns about how schools can and do adapt their planning to make sure that all their students will be accounted for in an emergency.   Join us in learning from Brad Stiles, M.A., Emergency Response Outreach Consultant at Colorado Office of School Safety (OSS). He offers his take on where we are at now and what families and school staff should consider when advocating for their Special Education students.

This is a reposted episode. Originally published December 2024.In this episode of The Biblical Languages Podcast, Kevin takes us through the nuances of some key Christmas passages.Referenced Resources:- Kevin's video responding to Dan McClellan: https://www.youtube.com/watch?v=7v132jB0KO4&t=96s- (book) The Mother of the Infant King by Christophe Rico and Peter Gentry: https://www.amazon.com/dp/1498230164- (article) The Accommodations of Joseph and Mary in Bethlehem: Κατάλυμα in Luke 2.7 by Stephen Carleson: https://www.cambridge.org/core/journals/new-testament-studies/article/abs/accommodations-of-joseph-and-mary-in-bethlehem-in-luke-27/E60EB9AEE5215FC0C989DE635DC80A7B- (blog post) Jesus wasn't born in a stable—and that makes all the difference by Ian Paul: https://www.psephizo.com/biblical-studies/jesus-wasnt-born-in-a-stable-and-that-makes-all-the-difference/As always, this episode is brought to you by Biblingo, the premier solution for learning, maintaining, and enjoying the biblical languages. Visit ⁠biblingo.org⁠ to learn more and start your 10-day free trial. If you enjoy this episode, be sure to subscribe on your favorite podcast app and leave us a review. You can also follow Biblingo on social media @biblingoapp to discuss the episode with us and other listeners.

JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, "Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for response to ICPI in mUC. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center. Today I am excited to be joined by Dr. Shilpa Gupta, Director of Genitourinary Medical Oncology at the Cancer Institute and co-leader of the GU Oncology Program at the Cleveland Clinic, and also lead author of the JCO PO article titled "Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma." At the time of this recording, our guest's disclosures will be linked in the transcript. Shilpa, welcome again to the podcast. Thank you for joining us today. Dr. Shilpa Gupta: Thank you, Rafeh. Honor to be here with you again. Dr. Rafeh Naqash: It is nice to connect with you again after two years, approximately. I think we were in our infancy of our JCO PO podcast when we had you first time, and it has been an interesting journey since then. Dr. Shilpa Gupta: Absolutely. Dr. Rafeh Naqash: Well, excited to talk to you about this article that you published. Wanted to first understand what is the genomic landscape of urothelial cancer in general, and why should we be interested in FGFR3 alterations specifically? Dr. Shilpa Gupta: Bladder cancer or urothelial cancer is a very heterogeneous cancer. And while we find there is a lot of mutations can be there, you know, like BRCA1, 2, in HER2, in FGFR, we never really understood what is driving the cancer. Like a lot of old studies with targeted therapies did not really work. For example, we think VEGF can be upregulated, but VEGF inhibitors have not really shown definite promise so far. Now, FGFR3 receptor is the only therapeutic target so far that has an FDA approved therapy for treating metastatic urothelial cancer patients, and erdafitinib was approved in 2019 for patients whose tumors overexpressed FGFR3 mutations, alterations, or fusions. And in the landscape of bladder cancer, it is important because in patients with non-muscle invasive bladder cancer, about 70 to 80% patients can have this FGFR3. But as patients become metastatic, the alterations are seen in, you know, only about 10% of patients. So the clinical trials that got the erdafitinib approved actually used archival tumor from local cancer. So when in the real world, we don't see a lot of patients if we are trying to do metastatic lesion biopsies. And why it is important to know this is because that is the only targeted therapy available for our patients right now. Dr. Rafeh Naqash: Thank you for giving us that overview. Now, on the clinical side, there is obviously some interesting data for FGFR3 on the mutation side and the fusion side. In your clinical practice, do you tend to approach these patients differently when you have a mutation versus when you have a fusion? Dr. Shilpa Gupta: We can use the treatment regardless of that. Dr. Rafeh Naqash: I recently remember I had a patient with lung cancer, squamous lung cancer, who also had a synchronous bladder mass. And the first thought from multiple colleagues was that this is metastatic lung. And interestingly, the liquid biopsy ended up showing an FGFR3-TACC fusion, which we generally don't see in squamous lung cancers. And then eventually, I was able to convince our GU colleagues, urologists, to get a biopsy. They did a transurethral resection of this tumor, ended up being primary urothelial and synchronous lung, which again, going back to the FGFR3 story, I saw in your paper there is a mention of FGFR3-TACC fusions. Anything interesting that you find with these fusions as far as biology or tumor behavior is concerned? Dr. Shilpa Gupta: We found in our paper of all the patients that were sequenced that 20% had the pathognomonic FGFR3 alteration, and the most common were the S249C, and the FGFR3-TACC3 fusion was in 45 patients. And basically I will say that we didn't want to generate too much as to fusion or the differences in that. The key aspect of this paper was that historically there were these anecdotal reports saying that patients who have FGFR alterations or mutations, they may not respond well to checkpoint inhibitors because they have the luminal subtype. And these were backed by some preclinical data and small anecdotal reports. But since then, we have seen that, and that's why a lot of people would say that if somebody's tumor has FGFR3, don't give them immunotherapy, give them erdafitinib first, right? So then we had this Phase 3 trial called the THOR trial, which actually showed that giving erdafitinib before pembrolizumab was not better. That debunked that myth, and we are actually reiterating that because in our work we found that patients who had FGFR3 alterations or fusions, and if they also have TMB-high, they actually respond very well to single agent immunotherapy. And that is, I think, very important because it tells us that we are not really seeing that so-called potential of resistance to immunotherapy in these patients. So to answer your question, yeah, we did see those differences, but I wouldn't say that any one marker is more prominent. Dr. Rafeh Naqash: The analogy is kind of similar to what we see in lung cancer with these mutations called STK11/KEAP1, which are also present in some other tumors. And one of the questions that I don't think has been answered is when you have in lung cancer, if you extrapolate this, where doublet or single agent immunotherapy doesn't do as well in tumors that are STK11 mutated. But then if you have a high TMB, question is does that TMB supersede or trump the actual mutation? Could that be one reason why you see the TMB-high but FGFR3 altered tumors in your dataset responding or having better outcomes to immunotherapy where potentially there is just more neoantigens and that results in a more durable or perhaps better response to checkpoint therapy? Dr. Shilpa Gupta: It could be. But you know, the patients who have FGFR alterations are not that many, right? So we have already seen that just patients with TMB-high respond very well to immunotherapy. Our last podcast was actually on that, regardless of PD-L1 that was a better predictor of response to immunotherapy. So I think it's not clear if this is adding more chances of response or not, because either way they would respond. But what we didn't see, which was good, that if they had FGFR3, it's not really downplaying the fact that they have TMB-high and that patients are not responding to immunotherapy. So we saw that regardless, and that was very reassuring. Dr. Rafeh Naqash: So if tomorrow in your clinic you had an individual with an FGFR3 alteration but TMB-high, I guess one could be comfortable just going ahead with immunotherapy, which is what the THOR trial as you mentioned. Dr. Shilpa Gupta: Yes, absolutely. And you know, when you look at the toxicity profiles of pembrolizumab and erdafitinib, really patients really struggle with using the FGFR3 inhibitors. And of course, if they have to use it, we have to, and we reserve it for patients. But it's not an easy drug to tolerate. Currently the landscape is such that, you know, frontline therapy has now evolved with an ADC and immunotherapy combinations. So really if patients progress and have FGFR3 alterations, we are using erdafitinib. But let's say if there were a situation where a patient has had chemotherapy, no immunotherapy, and they have FGFR3 upregulation and TMB-high, yes, I would be comfortable with using only pembrolizumab. And that really ties well together what we saw in the THOR trial as well. Dr. Rafeh Naqash: Going to the clinical applications, you mentioned a little bit of this in the manuscript, is combination therapies. You alluded to it a second back. Everything tends to get combined with checkpoint therapy these days, as you've seen with the frontline urothelial, pembrolizumab with an ADC. What is the landscape like as far as some of these FGFR alterations are concerned? Is it reasonable to combine some of those drugs with immune checkpoint therapy? And what are some of the toxicity patterns that you've potentially seen in your experience? Dr. Shilpa Gupta: So there was indeed a trial called the NORSE trial. It was a randomized trial but not a comparative cohort, where they looked at FGFR altered patients. And when they combined erdafitinib plus cetrelimab, that did numerically the response rates were much higher than those who got just erdafitinib. So yeah, the combination is definitely doable. There is no overlapping toxicities. But unfortunately that combination has not really moved forward to a Phase 3 trial because it's so challenging to enroll patients with such kind of rare mutations on large trials, especially to do registration trials. And since then the frontline therapy has evolved to enfortumab vedotin and pembrolizumab. I know there is an early phase trial looking at a next generation FGFR inhibitor. There is a triplet combination looking in Phase 1 setting with a next generation FGFR inhibitor with EV-pembro. However, it's not a randomized trial. So you know, I worry about such kinds of combinations where we don't have a path for registration. And in the four patients that have been treated, four or five patients in the early phase as a part of basket trial, the toxicities were a lot, you know, when you combine the EV-pembro and an FGFR3 inhibitor, we see more and more toxicity. So the big question is do we really need the "kitchen sink" approach when we have a very good doublet, or unless the bar is so high with the doublet, like what are we trying to add at the expense of patient toxicity and quality of life is the big question in my mind. Dr. Rafeh Naqash: Going back to your manuscript specifically, there could be a composite biomarker. You point out like FGFR in addition to FGFR TMB ends up being predictive prognostic there. So that could potentially be used as an approach to stratify patients as far as treatment, whether it's a single agent versus combination. Maybe the TMB-low/FGFR3 mutated require a combination, but the TMB-high/FGFR mutated don't require a combination, right? Dr. Shilpa Gupta: No, that's a great point, yeah. Dr. Rafeh Naqash: But again, very interesting, intriguing concepts that you've alluded to and described in this manuscript. Now, a quick take on how things have changed in the bladder cancer space in the last two years. We did a podcast with you regarding some biomarkers as you mentioned two years back. So I really would like to spend the next minute to two to understand how have things changed in the bladder cancer space? What are some of the exciting things that were not there two years back that are in practice now? And how do you anticipate the next two years to be like? Maybe we'll have another podcast with you in another two years when the space will have changed even more. Dr. Shilpa Gupta: Certainly a lot has happened in the two years, you know. EV-pembro became the universal frontline standard, right? We have really moved away from cisplatin eligibility in metastatic setting because anybody would benefit from EV-pembro regardless of whether they are candidates for cisplatin or not, which historically was relevant. And just two days ago, we saw that EV-pembro has now been approved for localized bladder cancer for patients who are cisplatin ineligible or refusing. So, you know, this very effective regimen moving into earlier setting, we now have to really think of good treatment options in the metastatic setting, right? So I think that's where a lot of these novel combinations may come up. And what else we've seen is in a tumor agnostic trial called the DESTINY-PanTumor trial, patients who had HER2 3+ on immunohistochemistry, we saw the drug approval for T-DXd, and I think that has kind of reinvigorated the interest in HER2 in bladder cancer, because in the past targeting HER2 really didn't work. And we still don't know if HER2 is a driver or not. And at ESMO this year, we saw an excellent study coming out of China with DV which is targeting HER2, and toripalimab, which is a Chinese checkpoint inhibitor, showing pretty much similar results to what we saw with EV-pembro. Now, you know, not to do cross-trial comparisons, but that was really an amazing, amazing study. It was in the presidential session. And I think the big question is: does that really tell us that HER2-low patients will not benefit? Because that included 1+, 2+, 3+. So that part we really don't know, and I think we want to study from the EV-302 how the HER2 positive patients did with EV and pembro. So that's an additional option, at least in China, and hopefully if it gets approved here, there is a trial going on with DV and pembro. And lastly, we've seen a very promising biomarker, like ctDNA, for the first time in bladder cancer in the adjuvant setting guiding treatment with adjuvant atezolizumab. So patients who were ctDNA positive derived overall survival and recurrence-free survival benefit. So that could help us select moving forward with more studies. We can spare unnecessary checkpoint inhibitors in patients who are not going to benefit. So I think there is a lot happening in our field, and this will help do more studies because we already have the next generation FGFR inhibitors which don't have the toxicities that erdafitinib comes with. And combining those with these novel ADCs and checkpoint inhibitors, you know, using maybe TMB as a biomarker, because we really need to move away from PD-L1 in bladder cancer. It's shown no utility whatsoever, but TMB has. Dr. Rafeh Naqash: Well, thank you so much, Shilpa, for that tour de force of how things have changed in bladder cancer. There used to be a time when lung and melanoma used to lead this space in terms of the number of approvals, the biomarker development. It looks like bladder cancer is shifting the trend at this stage. So definitely exciting to see all the new changes that are coming up. I'd like to spend another minute and a half on your career. You've obviously been a leader and example for many people in the GU space and beyond. Could you, for the sake of our early career especially, the trainees and other listeners, describe how you focused on things that you're currently leading as a leader, and how you shaped your career trajectory over the last 10 years? Dr. Shilpa Gupta: That's a really important question, Rafeh, and you and I have had these discussions before, you know, being an IMG on visas like you, and being in different places. I think I try to make the most of it, you know, instead of focusing on the setbacks or the negative things. Like tried to grab the opportunities that came along. When I was at Moffitt, got to get involved with the Phase 1 trial of pembrolizumab in different tumor types. And just keeping my options open, you know, getting into the bladder cancer at that time when I wanted to really do only prostate, but it was a good idea for me to keep my options open and got all these opportunities that I made use of. I think an important thing is to, like you said, you know, have a focus. So I am trying to focus more on biomarkers that, you know, we know that 70% patients will respond to EV-pembro, right? But what about the remaining 30%? Like, so I'm really trying to understand what determines hyperprogressors with such effective regimens who we really struggle with in the clinic. They really don't do well with anything we give them after that. So we are doing some work with that and also trying to focus on PROs and kind of patient-reported outcomes. And a special interest that I've now developed and working on it is young-onset bladder cancer. You know, the colorectal cancer world has made a lot of progress and we are really far behind. And bladder cancer has historically been a disease of the elderly, which is not the case anymore. We are seeing patients in their 30s and 40s. So we launched this young-onset bladder cancer initiative at a Bladder Cancer Advocacy Network meeting and now looking at more deep dive and creating a working group around that. But yeah, you know, I would say that my philosophy has been to just take the best out of the situation I'm in, no matter where I am. And it has just helped shape my career where I am, despite everything. Dr. Rafeh Naqash: Well, thank you again. It is always a pleasure to learn from your experiences and things that you have helped lead. Appreciate all your insights, and thank you for publishing with JCO PO. Hopefully we will see more of your biomarker work being published and perhaps bring you for another podcast in a couple of years. Dr. Shilpa Gupta: Yeah, thank you, Rafeh, for the opportunity. And thanks to JCO PO for making these podcasts for our readers. So thanks a lot. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Shilpa Gupta Stock and Other Ownership Interests: Company: BioNTech SE,  Nektar Consulting or Advisory Role: Company: Gilead Sciences, Pfizer, Merck, Foundation Medicine, Bristol-Myers Squibb/Medarex, Natera, Astellas Pharma, AstraZeneca, Novartis, Johnson & Johnson/Janssen Research Funding: Recipient: Your Institution Company: Bristol Myers Squibb Foundation, Merck, Roche/Genentech, EMD Serono, Exelixis, Novartis, Tyra Biosciences, Pfizer, Convergent Therapeutics, Acrivon Therapeutics, Flare Therapeutics, Amgen Travel, Accommodations, Expenses: Company: Pfizer, Astellas Pharma, Merck    

Supporting students with dyslexia doesn't have to feel overwhelming! In this episode, we're sharing science-backed dyslexia support strategies to help struggling readers build confidence and fluency. Learn how to use multisensory instruction, structured phonics, and effective accommodations to create a dyslexia-friendly learning environment.*Note: Since this episode first aired, The International Dyslexia Association released a new and updated version of their definition of dyslexia. You can find that definition here.In this episode, we'll talk about:What dyslexia really is (and what it isn't).Why phonemic awareness and phonics are essential for dyslexic learners.How to use multisensory techniques to improve reading skills.Accommodations that help dyslexic students succeed in the classroom.Show LinksDyslexia TrainingInternational Dyslexia Association's List of Accommodations & ModificationsJoin Malia on Instagram.Become a Science of Reading Formula member!Rate, Review, and FollowIf you loved this episode, please take a minute to rate and review my show! That helps the podcast world know that this show is worth sharing with other educators just like you.Scroll to the bottom, tap to rate with five stars, and select "Write a Review". Then let me know what you loved most about the episode!While you're there, be sure to follow the podcast. I'm adding a bunch of bonus episodes to the feed and I don't want you to miss out! 

In this week's episode of Chasing the Rabbit, the team kicks things off with Christmas stories, family traditions, and even a few Waffle House memories as they talk about the funny “accommodations” families make during the holidays.Then we shift gears into something that matters deeply for every believer and every family: how to get into the Bible with confidence.Eric and Jeremy recap their recent “How to Bible” event, walking through Bible translations, reading levels, study tools, apps, and how parents can disciple their kids by helping them choose (and actually use) the right Bible. Whether you're trying to build better habits, help your kids engage Scripture, or simply want a lighthearted Christmas-season episode, this one delivers a fun and meaningful conversation.Listen, laugh, and be encouraged as we make room—both in our homes and in our hearts—for Jesus this Christmas season.

HOUR 3: Are people abusing disability accommodations? Disney seems to think so. full 2080 Mon, 08 Dec 2025 22:00:00 +0000 tspt0S3jDEsyQiBJG3A6k71jVUxHTUsA news The Dana & Parks Podcast news HOUR 3: Are people abusing disability accommodations? Disney seems to think so. You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://playe

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

The US has a huge problem with everyone needing special accommodations in secondary education.

When I learned of Lauren Tetenbaum's work around workplace menopause advocacy, I knew I wanted her to come on the show.  Talking about menopause at work is long overdue.  When there is something that directly impacts 50% of our population, 100% of us are impacted in some way.  We need to be talking about menopause at work.  Period.  Lauren Tetenbaum, LCSW, JD, PMH-C is a licensed clinical social worker, women's rights advocate, writer, and mom dedicated to supporting and empowering women through life transitions. With experience as both a lawyer and a psychotherapist, Lauren specializes in counseling women navigating identity shifts related to motherhood, career, and reproductive health. Lauren frequently contributes thought leadership to media and professional organizations; she is the author of the 2025 book Millennial Menopause: Preparing for Perimenopause, Menopause, and Life's Next Period.  Listen in to hear Lauren share: Why reproductive healthcare is a workplace issue The perimenopause/menopause symptoms that impact women at work Accommodations workplaces can make that support women in perimenopause/menopause (that benefit others too!) Benefits that workplaces can easily add to improve healthcare access for midlife women When and how to prepare for perimenopause instead of waiting for it to “hit you” in a way that profoundly impacts your life The costs we are seeing for employers who are choosing to NOT address menopause in the workplace How men can advocate for menopause friendly policies, education, and accommodations in the workplace Links Mentioned:  Connect with Lauren: millennialmenopause.com Get Lauren's book: Millennial Menopause Lauren on IG: @thecounselaur: https://www.instagram.com/thecounselaur/ Lauren on LinkedIn: https://www.linkedin.com/in/laurenatetenbaum/ Organization: Let's Talk Menopause Organization: The Menopause Society [Dec 9th and Jan 8th] Shameless Rising: a 2-part workshop series to release the noise, reclaim your voice, and reignite your vision in 2026: saradean.com/rising [Open Enrollment] Join Sara's Aligned Leadership Incubator: saradean.com/aligned Hire me to speak: saradean.com/speaking Coach with me: https://saradean.com/executive-coaching-services Connect with me on LinkedIn: https://www.linkedin.com/in/saradeanspeaks Watch Shameless Leadership episodes on YouTube: https://www.youtube.com/@saradeanspeaks Learn more about your ad choices. Visit podcastchoices.com/adchoices

Comment on the Show by Sending Mark a Text Message.This episode is part of my initiative to provide access to important court decisions  impacting employees in an easy to understand conversational format using AI.  The speakers in the episode are AI generated and frankly sound great to listen to.  Enjoy!A top performer with a life-threatening migraine condition built a 15-year career, earned awards, and worked remotely with a documented accommodation—until a post-merger culture shift demanded office presence and everything changed. We walk you through the allegation-filled timeline: the hot leads routed to younger men in the New York office, the confrontation that preceded a stroke doctors tied to job stress, and the series of decisions that, the complaint says, turned a medical safeguard into a career liability.We dig into the mechanics of discrimination and retaliation claims: how account assignments can become tools of pretext, why a disputed Citadel loss matters years later, and what it means when a PIP leans on contested narratives despite recent high performance. You'll hear how the continuing violations doctrine can bridge older incidents into a timely hostile environment claim, and why plausibility at the motion-to-dismiss stage hinges on a minimal inference—not courtroom proof. The distinction between granting an ADA accommodation and honoring it in practice sits at the core: resources withheld for remote staff, an ultimatum to attend training in person despite written permission, and the message that office presence equals opportunity.We also examine leadership statements that allegedly acknowledged past bias, rapid promotions for younger male colleagues, and the juxtaposition of a 2023 sales excellence award with a 2024 PIP. The legal stakes are high: timeliness defenses, comparator debates, and whether penalizing a stroke survivor's accommodation can be seen as extreme and outrageous conduct. Ultimately, we ask a broader question many workplaces face now: when office-first culture collides with health, is performance enough to protect an employee whose life depends on remote work?If this deep dive helped you see the issues more clearly, follow the show, share this episode with a colleague, and leave a quick review telling us where you stand on accommodations versus culture. Your take might shape a future mailbag. If you enjoyed this episode of the Employee Survival Guide please like us on Facebook, Twitter and LinkedIn. We would really appreciate if you could leave a review of this podcast on your favorite podcast player such as Apple Podcasts. Leaving a review will inform other listeners you found the content on this podcast is important in the area of employment law in the United States. For more information, please contact our employment attorneys at Carey & Associates, P.C. at 203-255-4150, www.capclaw.com.Disclaimer: For educational use only, not intended to be legal advice.

As managers and employees, how can we ensure that we support equitable disability accommodations for everyone? The Americans with Disabilities Act (ADA) offers a wealth of protections, but many workers and leaders are unaware of what these protections entail. Luckily, there are experts like Rachel Shaw out there to shed light on their intricacies and help educate us all.Rachel is a leading strategist in workplace inclusion and disability compliance and the author of “The Disabled Workforce: What the ADA Never Anticipated.” She joins me to add clarity to the laws in place to protect people with disabilities—including mental health and pregnancy—and ensure we have access to an equitable work environment that allows us all to be productive contributors, whatever differences of ability we might experience in our lifetimes. Understand your rights and responsibilities around disability inclusion:The most proactive and effective way to ask for an accommodation;The essential accommodation process every organization needs to develop;How much it really costs companies to approve employee requests;What's missing from the ADA and how it's being addressed.Related Links:Connect with Rachel Shaw on LinkedIn - https://www.linkedin.com/in/rachel-shaw-00037745/Learn more about Rachel's work - https://rachelshaw.com/Buy “The Disabled Workforce” - https://www.amazon.com/Disabled-Workforce-What-Never-Anticipated/dp/1544708599Episode 390, How to Manage ADHD in the Workplace - https://www.bossedup.org/podcast/episode390Episode 460, Balancing Work with a Complicated Pregnancy - https://www.bossedup.org/podcast/episode460Episode 123, Pursuing a Promotion While Pregnant - https://www.bossedup.org/podcast/episode123Episode 335, What do mom-friendly Workplaces look like and how to create them - https://www.bossedup.org/podcast/episode335   Episode 311, How to Talk About Marital Status, Parental Status, and Pregnancy in the Interview - https://www.bossedup.org/podcast/episode311Episode 315, How to Talk About Disability or Chronic Illness in the Job Interview - https://www.bossedup.org/podcast/episode315LEVEL UP: a Leadership Accelerator for Women on the Rise - https://www.bossedup.org/levelupBossed Up Courage Community - https://www.facebook.com/groups/927776673968737/Bossed Up LinkedIn Group - https://www.linkedin.com/groups/7071888/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There is a specific moment in the life of a Human Resources professional that is fraught with a peculiar kind of tension. It happens when a door opens, an employee sits down, and they say, simply, "I need something to change."We like to think of the workplace as a rational machine, governed by clear inputs and outputs. But what happens when the machine encounters the messy, unpredictable reality of the human body? In this episode of Human Solutions, we explore the "messiest corner of HR": the medical accommodation.Host Pete Wright and AIM HR Solutions' Terry Cook take us into the labyrinth of the Americans with Disabilities Act (ADA). It turns out, the difference between a lawsuit and a success story often hinges on things we rarely think about—the precise wording of a job description, the speed of a reply, and the strange social dynamics of an office chair.We explore why the most dangerous thing a manager can do is try to be "nice" without a process, why "undue hardship" is much harder to prove than you think, and the uncomfortable silence HR must maintain when the rest of the staff starts asking why that guy got to work from home.It is a conversation about the friction between compassion and compliance, and why, sometimes, the best way to help a human being is to strictly follow the rules.In this episode, we cover:The "Magic Words" Myth: Why an employee never actually has to say "disability" or "accommodation" to trigger a legal obligation.The Interactive Process: Why the answer isn't "yes" or "no," but rather a conversation about what is safe and essential.The Trap of Benevolence: How granting a request off the books can create a precedent that makes future equity impossible.The Paradox of the Chair: A look at how a $1,000 ergonomic chair can disrupt the morale of an entire department—and why morale doesn't count as an "undue hardship".The Manager's Dilemma: How to train supervisors to handle the frustration of not being allowed to know why their employee is being treated differently.Links & NotesThe Job Accommodation Network (JAN): A critical toolkit for understanding workplace accommodations.AskJAN.orgCompliance Resources:ADA.govEEOC: Employer ResponsibilitiesAIM HR Helpline: For AIM members dealing with complex accommodation scenarios.Phone: 800-470-6277Email: helpline@aimnet.org AIM HR Solutions Training CatalogAIM members can reach the HR Helpline at 800-470-6277 or helpline@aimnet.org for inquiries Monday through Friday from 8:30 a.m. – 5:00 p.m. (EST). Email requests will be responded to within 24 hours. 

Sooner or later, most households will experience health or mobility issues of some kind. An injury, illness, or age-related loss of mobility will often exacerbate existing clutter problems. In episode #281 of The Clutter Fairy Weekly, Gayle Goddard, professional organizer and owner of The Clutter Fairy in Houston, Texas, explores steps we can take to plan ahead for changes and accommodations that injury, illness, or disability can necessitate in our homes.Show notes: https://cfhou.com/tcfw281The Clutter Fairy Weekly is a live webcast and podcast designed to help you clear your clutter and make space in your home and your life for more of what you love. We meet Tuesdays at noon (U.S. Central Time) to answer your decluttering questions and to share organizing tools and techniques, success stories and “ah-hah!” moments, seasonal suggestions, and timeless tips.To participate live in our weekly webcast, join our Meetup group, follow us on Facebook, or subscribe to our mailing list. You can also watch the videos of our webcast on YouTube.Support the show

Comment on the Show by Sending Mark a Text Message.Think your medical condition or disability doesn't “count” because it isn't visible or permanent? That assumption costs careers. We dig into how disability rights actually work on the ground, why silence helps employers more than employees, and the simple forms of “notice” that trigger your legal protections. From anxiety and migraines to Crohn's, postpartum depression, and recovery from surgery, the coverage is broader than most people think—and the bar for “substantially limits” is intentionally low.We walk through the ADA's three-part definition of disability, highlight how major life activities include concentration, communication, and working, and explain why timing often exposes retaliation. You'll hear practical language you can use with a manager or HR, how to document requests and meetings, and what a good faith interactive process looks like when it's done right. We also share a free resource—the Job Accommodation Network at askjan.org—that can join the conversation and help identify workable accommodations like flexible schedules, remote options, adjusted metrics, or short-term leave.Real-world patterns matter: denials without analysis, discipline after medical leave, and “regarded as” mistakes can all expose employers to liability. We unpack court trends that favor inclusion, including protections for temporary and episodic conditions and mental health. If you've been pushing through symptoms and blaming yourself for “performance,” it's time to flip the script. Accommodations are rights, not favors, and early, clear communication can protect both your health and your job. If this resonates, follow the show, share it with a colleague who needs it, and leave a review to help more workers find the support they deserve. If you enjoyed this episode of the Employee Survival Guide please like us on Facebook, Twitter and LinkedIn. We would really appreciate if you could leave a review of this podcast on your favorite podcast player such as Apple Podcasts. Leaving a review will inform other listeners you found the content on this podcast is important in the area of employment law in the United States. For more information, please contact our employment attorneys at Carey & Associates, P.C. at 203-255-4150, www.capclaw.com.Disclaimer: For educational use only, not intended to be legal advice.

You are listening to a presentation given at the 2025Michigan Conference Cedar Lake Campmeeting. We pray you will be blessed!

Want to learn more about Vodyssey or start your STR journey. Book a call here:https://meetings.hubspot.com/vodysseystrategysession/booknow?utm_source=vodysseycom&uuid=80fb7859-b8f4-40d1-a31d-15a5caa687b7Contact Ross:https://itineraryboss.com/https://www.instagram.com/rossalcorn33/?hl=enhttps://www.youtube.com/@ItineraryBosshttps://www.linkedin.com/in/rossalcornru/https://open.spotify.com/show/1mmMJ6z3JdEOUJKUjLh8bD?si=fd290a47a091494dTALKED ABOUT SERVICE:https://www.rakuten.com/FOLLOW US:https://www.facebook.com/share/g/16XJMvMbVo/https://www.instagram.com/vodysseyshawnmoorehttps://www.facebook.com/vodysseyshawnmoore/https://www.linkedin.com/company/str-financial-freedomhttps://www.tiktok.com/@vodysseyshawnmoore

College can feel overwhelming for students with ADHD, but support exists. In this episode, I talk with Hannah Choi—executive function coach and communications specialist at Beyond Booksmart. Hannah shares her personal ADHD story and practical tools to help college students build independence, manage their time, and advocate for what they need. From study strategies that actually work to understanding accommodations, we unpack how to set students up for a smoother transition into college.Whether you're a student, parent, or educator, you'll walk away with actionable strategies. We also explore gap years, what colleges are required to provide under ADA, and how executive function coaching builds confidence beyond academics.Meet Hannah Choi Hannah Choi, MA, is an executive function coach and Communications and Engagement Specialist at Beyond Booksmart. She helps college students and adults strengthen time management, task initiation, and self-advocacy skills. Hannah hosts the Focus Forward podcast, leads webinars, and facilitates motivation and accountability programs. She holds degrees in Psychology and American Sign Language from the University of Rochester and a Master's in Education from UC Santa Barbara. Hannah lives in Connecticut with her family. Episode Highlights [0:00] What studying really looks like with ADHD [2:26] Hannah's ADHD discovery and coaching path [11:09] Study strategies that build self-regulation [13:37] How to start practicing self-advocacy [15:52] Accommodations: from 504 to college [21:06] Top executive function skills before college [23:38] Managing all that “free time” [26:33] Building independence (without overparenting) [29:55] The case for gap years and transition programs [35:41] How EF skills impact life after graduation [38:50] Getting unstuck: motivation + task initiation [46:35] Final takeaway: it's never too late to change Connect with Hannah Choi:Instagram: @beyondbooksmartcoaching Website: https://www.beyondbooksmart.com/ Focus Forward Podcast: https://www.beyondbooksmart.com/podcast Thank you for tuning into "SuccessFULL with ADHD." If this episode has impacted you, remember to rate, follow, share, and review our podcast. Your support helps us reach and help more individuals navigating their journeys with ADHD.

When your child struggles with OCD, it's natural to want to ease their distress, but those well-meaning “helping” moments can actually feed OCD's control. In this episode, Natasha breaks down how to pull back accommodations safely and effectively, without creating unnecessary conflict or fear.You'll learn:What OCD accommodations really are and how they sneak into daily routinesWhy reducing them helps your child gain long-term confidenceHow to involve your child in the processWhat to do (and not do) when emotions run highHow to stay consistent and supportive as your child builds resiliencePulling back OCD accommodations isn't about being tough — it's about helping your child take their power back from OCD, one small step at a time.Get in-depth OCD support in my FREE parenting series starting this week. You can register at www.ATparentingsurvivalseries.comLinks mentioned in the show:Get a PDF handout of today's episodeSPACE Treatment Study Guide CourseEli Lebowitz's book Breaking Free of Child Anxiety and OCD & Alec Pollard's book When a Love On Won't Seek Mental Health TreatmentSPACE Treatment website, Alec Pollard's website, YouTube video on compulsive reassurance, YouTube video on compulsive confessing, Podcast on developing effective incentive plans***This podcast episode is sponsored by NOCD. NOCD provides online OCD therapy in the US, UK, Australia and Canada. To schedule your free 15 minute consultation to see if NOCD is a right fit for you and your child, go to https://go.treatmyocd.com/at_parentingThis podcast is for informational purposes only and should not be used to replace the guidance of a qualified professional. Parents, do you need more support?

Welcome back to the Bar Exam Toolbox podcast! Today, we're speaking with Chris Fromm - National Director of Curriculum and Assessment at Themis Bar Review - about strategies for tackling multiple-choice questions on the bar exam, including the upcoming NextGen format. We discuss how to manage your time effectively, leverage practice tools, and seek support during the challenging bar prep period. Note: This episode is sponsored by Themis Bar Review – the gold standard in bar exam preparation. With this special promotion, you can save $1,000 on any 2026 Themis Bar Review course using the code BAREXAMTB1000 at checkout. (This offer is valid until December 1st, 2025.) In this episode, we discuss: Why are multiple-choice questions stress-inducing for many people? Tips for approaching multiple-choice questions on the bar exam Effective time management and scheduling Turning to your support network for help Accommodations and focus strategies Six-option questions on the NextGen exam Resources: Themis Bar Review (https://www.themisbar.com/) Podcast Episode 18: Strategies for Mastering the MBE (https://barexamtoolbox.com/podcast-episode-18-strategies-for-mastering-the-mbe/) Podcast Episode 244: Spaced Repetition and Memorization During Bar Prep (w/Gabe Teninbaum) (https://barexamtoolbox.com/podcast-episode-244-spaced-repetition-and-memorization-during-bar-prep-w-gabe-teninbaum/) Podcast Episode 261: Quick Tips – Bar Exam Accommodations Basics (https://barexamtoolbox.com/podcast-episode-261-quick-tips-bar-exam-accommodations-basics/) Practice a Full Bar Exam Session – Go for the Gold (https://barexamtoolbox.com/practice-a-full-bar-exam-session-go-for-the-gold/) How to Plan Your Bar Exam Study Day for Maximum Success (https://barexamtoolbox.com/how-to-plan-your-bar-exam-study-day-for-maximum-success/) Manage Expectations Before Bar Prep Begins: Keeping Friends & Family on Your Side (https://barexamtoolbox.com/manage-expectations-before-bar-prep-begins-keeping-friends-family-on-your-side/) Download the Transcript (https://barexamtoolbox.com/episode-332-mastering-bar-exam-multiple-choice-questions-w-chris-fromm-from-themis/) If you enjoy the podcast, we'd love a nice review and/or rating on  Apple Podcasts (https://itunes.apple.com/us/podcast/bar-exam-toolbox-podcast-pass-bar-exam-less-stress/id1370651486) or your favorite listening app. And feel free to reach out to us directly. You can always reach us via the contact form on the Bar Exam Toolbox website (https://barexamtoolbox.com/contact-us/). Finally, if you don't want to miss anything, you can sign up for podcast updates (https://barexamtoolbox.com/get-bar-exam-toolbox-podcast-updates/)! Thanks for listening! Alison & Lee

In this podcast recorded at our recent Corporate Labor and Employment Counsel Exclusive® seminar, Tae Phillips (shareholder, Birmingham), Jim Paul (shareholder, St. Louis/Tampa), and Scott Kelly (shareholder, Birmingham) continue their discussion of the EEOC's evolving enforcement priorities—this time addressing religious discrimination, harassment, and accommodations in the workplace. Jim (who is co-chair of the firm's Disability Access Practice Group) examines recent trends, including the rise in religious accommodation requests, the impact of federal executive orders, and the challenges employers face in navigating religious and political overlap in employee requests. The conversation highlights the complexities of accommodating diverse religious beliefs while maintaining compliance with Title VII of the Civil Rights Act and fostering a respectful work environment.

The Push-Pull of ADHD and Autism: Stretching Without Breaking In this candid conversation, Patricia Young (she/her) and B Lourenco (she/her) dive deep into the realities of living with ADHD, autism, and other forms of neurodivergence. They explore the push-pull between self-accommodation and stretching ourselves, how shame and internalized ableism impact daily life, and what it means to create realistic support systems at home, in relationships, and in the workplace. Expect raw honesty, relatable stories, and practical insights for navigating neurodivergent life. WHAT YOU'LL HEAR IN THIS EPISODE · The ongoing "driver's seat battle" between ADHD and autism. · The push-pull between making accommodations and stretching ourselves beyond comfort. · Parenting a neurodivergent young adult while balancing when to push and when to allow rest. · Task initiation struggles — from making banana bread to cooking meals. · Body doubling as a powerful tool to reduce shame and spark motivation. · The "crisper/rotter" effect — guilt over wasted food and executive dysfunction. · Financial and practical impacts of task initiation challenges. · How privilege plays into having options like prepared or frozen meals when cooking feels impossible. · The cost of pushing through fatigue and flares with conditions like POTS and MCAS. · "Future me" thinking — and the difficulties neurodivergent folks have with impermanence. · Shame as the "ice cream scoop" on top of disability struggles. · Why diagnosis matters: language helps reduce shame and prevent repeating harmful patterns. · How powerlessness, and an attempt to gain autonomy can show up in small, reactive choices (like leaving a Facebook group). · Sensory sensitivities in family systems — how lack of accommodations can lead to dysfunction. · Practical accommodations for noise-sensitive parents and their kids. · Workplace challenges: 40-hour weeks, return-to-office pressures, and capitalism's rigidity. · Creative problem-solving in disabled and neurodivergent communities. · The deep fear of being uncared for and alone if we can't keep up. · Hyper-independence and isolation in the ADHD/autistic community. · Internalized ableism and the "shoulds" that drive shame and burnout. · Neurodivergence as a dynamic disability — what's possible one day isn't always possible the next. · Radical acceptance as a path toward reducing judgment and finding relief. SOUND BITES · "It begs the question of, okay, is that okay? Can we just say that's how it is?" – B Lourenco · "Instead of putting our energy into addressing the gap, folks will take the great divide and then put a scoop of shame on top of it." – B Lourenco · "All the terrible things that we tell ourselves… if I didn't have that awareness, I'd just keep repeating these patterns." – Patricia Young · "In order to truly accommodate ourselves, we have to acknowledge that it's as hard as it is and that we're as disabled as we are." – B Lourenco · "Sometimes I have to ask myself, what if what you're going through is exactly where you need to be?" – Patricia Young SENSITIVITY IS NOTHING TO APOLOGIZE FOR; IT'S HOW YOUR BRAIN IS WIRED You are not broken. You were shaped by systems that weren't built for you. You deserve rest, joy, and support exactly as you are. TOPICS COVERED (please adjust for addition of introduction) 00:00 Navigating Neurodivergence: A Personal Journey 02:59 Understanding Accommodations: Balancing Needs and Expectations 05:48 The Push-Pull of Task Initiation and Self-Care 08:33 Shame and Support: The Role of Community 11:35 The Impact of Environment on Neurodivergent Individuals 14:26 Workplace Challenges: The Struggle for Accommodations 17:16 Building Bridges: Community and Creative Solutions 20:00 Radical Acceptance: Embracing Our Reality 22:48 The Journey of Self-Discovery and Identity 25:42 The Dynamic Nature of Neurodivergence 29:02 Finding Joy in the Present Moment 31:47 The Bigger Picture: Building a Better Future 34:47 Conclusion: Resources and Future Endeavors PODCAST HOST Patricia Young (she/her) was a Licensed Clinical Social Worker for over 17 years, but she is now exclusively providing coaching. She knows what it's like to feel like an outcast, misfit, and truthteller. Learning about the trait of being a Highly Sensitive Person (HSP), then learning she is AuDHD with a PDA profile, OCD and RSD, helped Patricia rewrite her history with a deeper understanding, appreciation, and a sense of self-compassion. She created the podcasts Unapologetically Sensitive and Unapologetically AuDHD to help other neurodivergent folks know that they aren't alone, and that having a brain that is wired differently comes with amazing gifts, and some challenges. Patricia works online globally working individually with people, and she teaches Online Courses for neurodivergent folks that focus on understanding what it means to be a sensitive neurodivergent. Topics covered include: self-care, self-compassion, boundaries, perfectionism, mindfulness, communication, and creating a lifestyle that honors you Patricia's website, podcast episodes and more: www.unapologeticallysensitive.com PODCAST GUEST B Lourenco, MA, LMHC (she/her) is a licensed mental health counselor, educator, advocate, and activist. B has been working in community support for nearly 20 years and is committed to social change on all system levels. Seeing mental health advocacy as a way to serve the community, she earned a Master of Arts degree in Clinical Psychology, with a Systems Emphasis, in 2015 and began her private practice, B Lourenco Therapy in 2017. B has also worked in the public school system, providing support to students with behavioral issues that made attending school challenging for them. Highly trained in Applied Behavior Analysis (ABA), B became a district-wide expert in supporting neurodivergent students. It was during this work that she began to be critical of the medical models of support for neurodivergence, including ABA. Making the shift from the medical to the Neurodiversity-affirming model has allowed her to finally identify her own neurodivergence, including Autism and ADHD. Combining her lived experience of neurodivergence, along with years of anti-oppression work, B is passionate about helping others untangle themselves from harmful practices and align themselves with those that instead support marginalized communities. In addition to CE events for healthcare providers, she has also been a speaker on panels and podcasts, and also facilitates community based workshops. https://www.blourencotherapy.com LINKS Cascadia Training: https://cascadia-training.com Imani Barbarin—crutches_and_spice IG https://www.instagram.com/crutches_and_spice/ To write a review in itunes: click on this link https://itunes.apple.com/us/podcast/unapologetically-sensitive/id1440433481?mt=2 select "listen on Apple Podcasts" chose "open in itunes" choose "ratings and reviews" click to rate the number of starts click "write a review" Website--www.unapologeticallysensitive.com Facebook-- https://www.facebook.com/Unapologetically-Sensitive-2296688923985657/ Closed/Private Facebook group Unapologetically Sensitive-- https://www.facebook.com/groups/2099705880047619/ Instagram-- https://www.instagram.com/unapologeticallysensitive/ Youtube-- https://www.youtube.com/channel/UCOE6fodj7RBdO3Iw0NrAllg/videos?view_as=subscriber Tik Tok--https://www.tiktok.com/@unapologeticallysensitiv Unapologetically AuDHD Podcast-- https://unapologeticallysensitive.com/unapologeticallyaudhd/ e-mail-- unapologeticallysensitive@gmail.com Show hashtag--#unapologeticallysensitive Music-- Gravel Dance by Andy Robinson www.andyrobinson.com

On this episode of The Steve Dangle Podcast, 00:00 Leafs beat the Preds 54:45 A great Ducks giveaway 1:02:30 Rangers lose at home again 1:11:00 The Sharks owner speaks 1:25:30 A Sharks giveaway 1:28:00 Adam's Pittsburgh fat guy corner 1:42:00 Accommodations for NHLers at the Olympics Donate to Steve's Easter Seals page: https://eastersealsontario.akaraisin.com/ui/lindros2025/p/078df4e3c0c444d59a551259d78a749e Donate to Adam's Easter Seals page: https://eastersealsontario.akaraisin.com/ui/lindros2025/p/12938347f56e4b2eab06c3a423a727f6 Donate to Jesse's Easter Seals page: https://eastersealsontario.akaraisin.com/ui/lindros2025/p/f58403a20caa4b47a17e19cf86c198d9 Visit this episode's sponsors: Grab a pack today.  Visit your local Tim Hortons, or download the Tims App, to start collecting Tim Horton's NHL Hockey Trading Cards. Grab your EXCLUSIVE NordVPN Deal by going to https://nordvpn.com/dangle to get a Huge Discount off your NordVPN Plan + 4 additional months on top! It's completely risk-free with Nord's 30-day money-back guarantee! Hope in Every Step is more than a walk — it's a movement. Held this year at Spencer Smith Park in Burlington on November 1st, the event brings our community together to stand against gender-based violence. Visit https://hope-in-every-step.raiselysite.com/donate for more information. Join us at The Rec Room: https://sdpn.ticketspice.com/sdp-x-the-rec-room Join Drew & Stew Pick Em' ➡️ https://app.sparc.fun/point-spread/dspe Check out https://sdpn.ca/events to see The Steve Dangle Podcast live! Subscribe to the sdpn YouTube Channel: https://www.youtube.com/@sdpn?sub_confirmation=1Join - SDP VIP: YouTube: https://www.youtube.com/channel/UC0a0z05HiddEn7k6OGnDprg/join Apple Podcasts: https://apple.co/thestevedanglepodcast Spotify: https://podcasters.spotify.com/pod/show/sdpvip/subscribe - Follow us on Twitter: @Steve_Dangle, @AdamWylde, & @JesseBlake Follow us on Instagram: @SteveDangle, @AdamWylde, & @Jesse.BlakeJoin us on Discord: https://discord.com/invite/MtTmw9rrz7 For general inquiries email: info@sdpn.ca Reach out to https://www.sdpn.ca/sales to connect with our sales team and discuss the opportunity to integrate your brand within our content! Learn more about your ad choices. Visit megaphone.fm/adchoices

Parents often rely on their usual parenting strategies to help their child with OCD — but those same strategies can actually backfire. In this episode, I break down the most common approaches parents try and explain why they don't work when it comes to OCD.If you've ever felt stuck, repeating the same things without progress, this episode will help you understand why and what to do differently.To get the PDF handout that supplements this episode go to www.natashadaniels.com/episode440✨ Get 50% off all my courses and workshops until December 18, 2025 11:59pm in honor of OCD Awareness Week. Go to AT Parenting Survival School and use the coupon code OCDAWARENESS2025.Links mentioned in podcast:Podcast: Validation vs Accommodations in OCDPodcast: Developing Effective Incentive PlansReel: Distraction vs Refocusing***This podcast episode is sponsored by NOCD. NOCD provides online OCD therapy in the US, UK, Australia and Canada. To schedule your free 15 minute consultation to see if NOCD is a right fit for you and your child, go tohttps://go.treatmyocd.com/at_parentingThis podcast is for informational purposes only and should not be used to replace the guidance of a qualified professional.Parents, do you need more support?

Thanks for joining me, Holly Blanc Moses - The Mom/Neurodivergent Therapist, on The Autism ADHD Podcast. Is a neurodivergent student in your life struggling at school?  You're not alone—and there ARE supports that actually work. In this episode, I'm breaking down 5 game-changing school accommodations based on what parents, therapists, and educators are searching for most: communication supports, sensory regulation, executive functioning help, and more. These aren't vague suggestions—they're real examples you can implement in the classroom, recommend in evaluations, or request in IEP and 504 meetings. These 5 supports help in the areas of communication, regulation, executive functioning, writing, social interaction and mental health!  Perfect For: Parents preparing for IEP or 504 meetings and advocating for your child's needs. Therapists identifying school supports that will help clients emotionally, socially and academically. Educators looking for practical classroom strategies that work.  

Beau Martonik heads to Nebraska for an early-season deer camp with Thomas & Nate Krick (Identical Draw), Ben Dettamanti (Shed Crazy), Joel Burham (Whitetail Fit), and Josh Ilderton (The Untamed). The crew dives into what makes deer camp special—camaraderie, laughs, and lessons learned along the way. From spider stick pranks and quicksand mishaps to scouting strategies and close encounters, this episode of the East Meets West Hunt podcast captures the spirit of chasing whitetails together. Topics: 00:00:00 - Intro 00:04:11 – Introductions 00:06:30 – The Idea Behind This Camp 00:11:13 – Ben's Whitetail Perspective 00:13:07 – Spider Stick Shenanigans 00:15:25 – The Food Sources Debate 00:21:05 – The Quicksand Experience 00:23:41 – The Last Stand 00:29:07 – Ben's Shed Tour 00:32:05 – Nate's Buck 00:51:03 – Guest Switch - Josh Ilderton and Joel Burham 00:55:21 – Camp Life and Accommodations 01:00:22 – Hunting Timber vs. Agriculture 01:15:31 – Evening Strategies 01:22:36 – Wrapping Up the Adventure Resources: Joel Burham (Whitetail Fit) - YouTube and IG Identical Draw - YouTube and IG The Untamed - YouTube and IG Shed Crazy - YouTube and IG Instagram:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@eastmeetswesthunt⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@beau.martonik⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠East Meets West Outdoors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Shop Hunting Gear and Apparel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.eastmeetswesthunt.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube: Beau Martonik - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCQJon93sYfu9HUMKpCMps3w⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Partner Discounts and Affiliate Links: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.eastmeetswesthunt.com/partners⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Amazon Influencer Page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/beau.martonik⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices